Its good to have a published report validating things we shareholders already know.
While I love the 12mth target price, I think we need the benefit of getting past Phase II results. NNZ-2566 may be the ducks nuts in pre-clinical but it really needs validation in humans to get us noticed by the big end of town.
If we get it, 12c will be too cheap for this stock.
bell potter research report - 12c target, page-180
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.64 |
Change
-1.070(6.40%) |
Mkt cap ! $2.043B | |||
| Open | High | Low | Value | Volume |
| $16.61 | $16.65 | $15.54 | $4.184M | 262.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 351 | $15.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.65 | 482 | 8 |
View Market Depth
| Last trade - 13.16pm 18/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |